Skip to main content
Log in

Effects of the opiate agonist loperamide on pituitary-adrenal function in patients with suspected hypercortisolism

  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

In the present work the possible use of loperamide, an opiate agonist, in the dynamic evaluation of patients with suspected hypercortisolism was investigated. The effects of loperamide on plasma ACTH and Cortisol levels were evaluated in normal subjects and in 58 patients with suspected Cushing’s syndrome. The results were compared to those obtained after the overnight dexamethasone suppression test. In normal subjects plasma ACTH and Cortisol levels were significantly (p < 0.005) suppressed by both loperamide (16 mg po) and dexamethasone (1 mg po). In 17 patients, in whom the diagnosis of Cushing’s syndrome was confirmed by subsequent investigations, neither loperamide or dexamethasone inhibited Cortisol (from a baseline of 606 ± 55 nmol/L) to a nadir of 502 ± 43 nmol/L and 539 ± 50 nmol/L, respectively) and ACTH concentration (from a basal level of 70.1 +11.8 pg/ml to a nadir of 46.0 ± 8.6 pg/ml and 54.3 ± 7.5 pg/ml, respectively). In 34 patients, in whom the suspect of hypercortisolism was ruled out, either loperamide or dexamethasone suppressed the pituitary-adrenal axis: Cortisol and ACTH levels significantly fell from 417 ± 24 nmol/L and 28.3 ± 3.5 pg/ml to 60 ± 6 nmol/L and 14.4 ± 1.4 pg/ml after loperamide and to 26 ± 4 nmol and 16.4 ± 1.7 pg/ml after dexamethasone. In 7 patients discordant responses were observed. In 3 patients treated with antiepileptic drugs ACTH and Cortisol levels were inhibited by loperamide, but not by dexamethasone. In 4 other patients a normal suppression was induced by dexamethasone, but not by loperamide: in 2 cases the suspected hypercortisolism was definitely ruled out while in the other two no definitive diagnosis could be established. In these series of patients, the loperamide test equals the 1 mg dexamethasone suppression test in terms of sensitivity, specificity, diagnostic accuracy and predictive value. In conclusion: i) Loperamide administration is practical and reliable in testing the pituitary-adrenal function; ii) The procedure needs only three and half h to be completed and thus it is suitable and compliant to outpatients; iii) Loperamide might be useful in patients in some conditions (drug interference), in which the low-dose dexamethasone test has some limitations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Stubbs W.A, Delitala G., Jones A., Jeffcoate W.J., Edwards C.R.W., Ratter S.J., Besser G.M., Bloom F.R., Alberti K.G.M.M. Hormonal and metabolic responses to an enkephalin analogue in normal man. Lancet 2: 1225, 1978.

    Article  PubMed  CAS  Google Scholar 

  2. Del Pozo E., Von Graffenried B., Brownell J., Derrer F., Marbach P. Endocrine effect of a methionine-enkephalin derivative (FK 33–824) in man. Horm. Res. 13: 90, 1980.

    Article  PubMed  Google Scholar 

  3. Gaillard R.C., Grossman A., Smith R., Rees L.H., Besser G.M. The effects of a met-enkephalin analogue on ACTH, β-LPH, β-endorphin and met-enkephalin in patients with adrenocortical disease. Clin. Endocrinol. (Oxf.) 14: 471, 1981.

    Article  CAS  Google Scholar 

  4. Allolio B., Winkelmann W., Hipp F.X., Karlen D., Mies R. Effects of a met-enkephalin on adrenocorticotropin (ACTH), growth hormone and prolactin in patients with ACTH hypersecretion. J. Clin. Endocrinol. Metab. 55: 1, 1982.

    Article  PubMed  CAS  Google Scholar 

  5. Ambrosi B., Bochicchio D., Faglia G. Loperamide, an opiate analogue, inhibits plasma ACTH levels in patients with Addison’s disease. Clin. Endocrinol. (Oxf.) 24: 483, 1986.

    Article  CAS  Google Scholar 

  6. Ambrosi B., Bochicchio D., Riva E., Faglia G. Influence of loperamide on ACTH, GH and PRL levels in patients with ACTH hypersecretion. Acta Endocrinol. (Kbh.) 256(Suppl. 256): Abs. 201, 1983.

    Google Scholar 

  7. Deuss U., Allolio B., Kaulen D., Fischer H., Winkelmann W. Effects of high-dose and low-dose naloxone on plasma ACTH in patients with ACTH hypersecretion. Clin. Endocrinol. (Oxf.) 22: 273, 1985.

    Article  CAS  Google Scholar 

  8. Allolio B., Deuss U., Kaulen D., Leonhardt U., Kallabis D., Hamel E., Winkelmann W. FK 33–824, a met-enkephalin analog, blocks Corticotropin-Releasing Hormone-induced Adrenocorticotropin secretion in normal subjects but not in patients with Cushing’s disease. J. Clin. Endocrinol. Metab. 63: 1427, 1986.

    Article  PubMed  CAS  Google Scholar 

  9. Baranowska B., Dorobek W., Misiorowski W., Jeske W., Abdel-Fattah M.H. The effect of naloxone on ACTH and β-endorphin in patients with Cushing’s disease. Acta Endocrinol. (Kbh.) 110: 170, 1985.

    CAS  Google Scholar 

  10. Mackerer R.C., Clay G.A., Dajani E.Z. Loperamide binding to opiate receptor sites of brain and myenteric plexus. J. Pharmacol. Exp. Therap. 199: 131, 1976.

    CAS  Google Scholar 

  11. Bochicchio D., Ambrosi B., Faglia G. Loperamide, an opiate analog, differently modifies the ACTH responses to CRH and Lysine-vasopressin in patients with Addison’s disease. Neuroendocrinology 48: 611, 1988.

    Article  PubMed  CAS  Google Scholar 

  12. Galen R.S., Gambino S.R. Beyond Normality: The Predictive value and Efficiency of Medical Diagnoses. John Wiley & Sons, New York, 1975.

    Google Scholar 

  13. Tolis G., Jukier L., Wiesen M., Krieger D.T. Effect of naloxone on pituitary hypersecretory syndromes. J. Clin. Endocrinol. Metab. 54: 780, 1982.

    Article  PubMed  CAS  Google Scholar 

  14. Caro J.F., Meikle A.W., Check J.H. “Normal suppression” to dexamethasone in Cushing’s disease: an expression of decreased metabolic clearance for dexamethasone. J. Clin. Endocrinol. Metab. 47: 667, 1978.

    Article  PubMed  CAS  Google Scholar 

  15. Crapo L. Cushing’s syndrome: a review of diagnostic tests. Metabolism 21: 955, 1979

    Article  Google Scholar 

  16. Allolio B., Winkelmann W., Kaulen D., Reincke M., Jaursch-Hancke C., Schrell U., Fahlbusch R. A reversible defect in the opioidergic control of ACTH release in Cushing’s disease. In: Landolt A.M., Heitz P.U., Zapf J., Girard J., Del Pozo E. (Eds.), Advances in pituitary adenoma research. Pergamon Press, Oxford, 1988, p. 349.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ambrosi, B., Bochicchio, D., Ferrario, R. et al. Effects of the opiate agonist loperamide on pituitary-adrenal function in patients with suspected hypercortisolism. J Endocrinol Invest 12, 31–35 (1989). https://doi.org/10.1007/BF03349913

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03349913

Key-words

Navigation